

*f. Sellers*

March 22, 1978

William R. Tabor, M.D.  
A. H. Robins Co.  
Richmond, Virginia 23220

Dear Bill,

I was saddened by your note of March 13 indicating that further study of lenperone was suspended. Having followed the progress of the development of this drug from its early clinical trials, I know how much effort (and dollars) have been expended. I do not know where lenperone would have fallen in the therapeutic spectrum, but we are all losers -- patients and physicians alike -- in losing the opportunity to test the compound in the clinical marketplace, where so many of the applications have been discovered.

I do hope that you have a replacement on the way.

We no longer have any supplies on hand, and will follow your admonition regarding our records.

My best regards.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry